- Home
- UTL vs GYRE Comparison
UTL vs GYRE Comparison
Compare UTL & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTL
- GYRE
- Stock Information
- Founded
- UTL 1984
- GYRE 2002
- Country
- UTL United States
- GYRE United States
- Employees
- UTL 544
- GYRE N/A
- Industry
- UTL Power Generation
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- UTL Utilities
- GYRE Health Care
- Exchange
- UTL Nasdaq
- GYRE Nasdaq
- Market Cap
- UTL 921.2M
- GYRE 990.4M
- IPO Year
- UTL N/A
- GYRE N/A
- Fundamental
- Price
- UTL $58.72
- GYRE $8.88
- Analyst Decision
- UTL Hold
- GYRE
- Analyst Count
- UTL 1
- GYRE 0
- Target Price
- UTL $55.00
- GYRE N/A
- AVG Volume (30 Days)
- UTL 64.8K
- GYRE 209.4K
- Earning Date
- UTL 05-06-2025
- GYRE 05-19-2025
- Dividend Yield
- UTL 3.07%
- GYRE N/A
- EPS Growth
- UTL 3.86
- GYRE N/A
- EPS
- UTL 2.93
- GYRE 0.05
- Revenue
- UTL $494,800,000.00
- GYRE $105,757,000.00
- Revenue This Year
- UTL $16.37
- GYRE $22.01
- Revenue Next Year
- UTL $5.20
- GYRE $88.14
- P/E Ratio
- UTL $20.07
- GYRE $184.70
- Revenue Growth
- UTL N/A
- GYRE N/A
- 52 Week Low
- UTL $48.36
- GYRE $6.11
- 52 Week High
- UTL $63.52
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- UTL 61.91
- GYRE 51.54
- Support Level
- UTL $56.45
- GYRE $7.03
- Resistance Level
- UTL $58.74
- GYRE $8.44
- Average True Range (ATR)
- UTL 1.72
- GYRE 1.12
- MACD
- UTL 0.14
- GYRE 0.23
- Stochastic Oscillator
- UTL 93.28
- GYRE 92.33
About UTL UNITIL Corporation
Unitil Corp is a holding company, through its subsidiaries it is engaged in the local distribution of electricity and natural gas throughout its service territories in the states of New Hampshire, Massachusetts, and Maine. The Company has two operating and reportable segments: Utility Electric Operations and Utility Gas Operations. Majority of revenue is gained from Electric Segment.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.